-
Retrophin (RTRX) PT Lowered to $45 at BMO Capital on Phase 3 Trial Initiation for Sparsentan; '75% Probability of Success'
-
Retrophin (RTRX) Bullish View Reiterated at BMO Following Conference Presentation
-
Retrophin to Present at the BMO Capital Markets Healthcare Conference
-
Retrophin (RTRX) PT Raised to $46 at BMO as Details Strengthen DUET Data
-
Retrophin (RTRX) Bullish Stance Reiterated at BMO as RE-024 Gets Accelerated Path To Market
-
Today's Biotech Upside Could Be Just the Start - BMO Capital (IBB) (XBI)
-
Retrophin (RTRX): DUET Data At ASN Could Preview FDA - BMO
-
Retrophin (RTRX) PT Raised to $40 at BMO Capital
-
Retrophin (RTRX) Setup Into DUET Data Remains Favorable - BMO
-
BMO Capital Starts Retrophin (RTRX) at Outperform

